IP Library Granted Patent US 9,309,321
Granted Patent B2
US 9,309,321 · App. 13/861,619 · Granted Apr 12, 2016

Monoclonal antibody specifically recognizing an epitope for switching to Th17 cell

Inventor: Byoung Se Kwon (Goyang-si, KR)
Assignee: National Cancer Center
C07K16/2878C07K7/06C07K14/70578C07K16/3061A61K2039/505C07K2317/21C07K2317/34C07K2317/55C07K2317/74C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,309,321
App. No.
13/861,619
Granted
Apr 12, 2016
Kind
B2
Abstract

The present invention relates to a novel epitope to convert T cell to type 17 helper T (T H 17) cell. Specifically, the present invention relates to an epitope constituting the 41 st to 50 th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to T H 17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method, for enhancing immunity using the antibody.

Claims (8)

1. A monoclonal antibody specifically recognizing an epitope of activation-inducible tumor necrosis factor receptor (AITR), wherein the epitope is represented by SEQ ID No. 2.

2. The monoclonal antibody of claim 1 , which comprises a heavy chain variable region comprising heavy chain complementarity-determining region 1 (CDR1) represented by SEQ ID No. 6; heavy chain CDR2 represented by SEQ ID No. 7; and heavy chain CDR3 represented by SEQ ID No. 8, and a light chain variable region comprising light chain CDR1 represented by SEQ ID No. 10; light chain CDR2 represented by SEQ ID No. 11; and light chain CDR3 represented by SEQ ID No. 12.

3. The monoclonal antibody of claim 2 , which comprises an amino acid sequence of heavy chain variable region represented by SEQ ID No. 5 and an amino acid sequence of light chain variable region represented by SEQ ID No. 9.

4. The monoclonal antibody of claim 2 , which comprises an amino acid sequence of a heavy chain variable region represented by SEQ ID No. 15, and an amino acid sequence of a light chain variable region represented by SEQ ID No. 16.

5. A polynucleotide encoding the antibody of claim 1 .

6. An expression vector comprising the polynucleotide of claim 5 .

7. A transformant introduced with the vector of claim 6 .

8. A method for treating fungal or bacterial infection, comprising administering the antibody of claim 1 to a subject in need thereof.

Assignments (3)
CHANGE OF ADDRESS Recorded Jul 26, 2021
From: EUTILEX CO., LTD.
To: EUTILEX CO., LTD.
Reel/Frame 057044/0548 →
NUNC PRO TUNC ASSIGNMENT Recorded Feb 9, 2017
From: NATIONAL CANCER CENTER
To: EUTILEX CO., LTD.
Reel/Frame 041215/0798 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2013
From: KWON, BYOUNG SE
To: NATIONAL CANCER CENTER
Reel/Frame 031123/0807 →
Priority Claims (2)
KR 10-2012-0061791 · Jun 8, 2012 · national
KR 10-2012-0088646 · Aug 13, 2012 · national
Continuity (1)
Related Publication 20140072565A1 · Mar 13, 2014